Review of Male Breast Carcinoma Cases
Author Information
Author(s): G. Ribeiro
Primary Institution: Christie Hospital & Holt Radium Institute
Hypothesis
What are the survival rates and treatment outcomes for male breast carcinoma patients?
Conclusion
The study found that the corrected survival rates for male breast carcinoma patients improved with the use of adjuvant Tamoxifen treatment.
Supporting Evidence
- Corrected survival rates were 52%, 38%, and 36% at 5, 10, and 15 years respectively.
- Adjuvant Tamoxifen treatment improved 5-year survival from 28% to 55%.
- 86% of tumors tested showed positive hormone receptor activity.
Takeaway
This study looked at 301 men with breast cancer and found that those who got a specific medicine called Tamoxifen lived longer than those who didn't.
Methodology
The clinical records of male breast carcinoma patients were analyzed, focusing on survival rates and treatment outcomes over a maximum follow-up of 15 years.
Potential Biases
There may be bias due to the reliance on historical controls for treatment comparisons.
Limitations
The study is limited by the rarity of male breast carcinoma, making it difficult to conduct controlled trials.
Participant Demographics
The mean age of participants was 63 years, with a majority presenting in their fifth and sixth decades.
Statistical Information
P-Value
<0.0001
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website